Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Iovance Biotherapeutics Inc
(NQ:
IOVA
)
8.550
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Iovance Biotherapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back
November 23, 2024
Via
The Motley Fool
2 Innovative Stocks That Could Deliver Outsize Returns
November 22, 2024
Via
The Motley Fool
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
November 16, 2024
Via
The Motley Fool
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
November 07, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
A Peek at Iovance Biotherapeutics's Future Earnings
November 06, 2024
Via
Benzinga
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
October 31, 2024
Iovance also to Participate in Upcoming November Conferences
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Is Iovance Biotherapeutics Stock a Buy?
October 04, 2024
The biotech is making important breakthroughs, but is that enough?
Via
The Motley Fool
Why Iovance Biotherapeutics Stock Triumphed on Thursday
October 24, 2024
With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.
Via
The Motley Fool
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
September 26, 2024
This biotech's growth story is going to start moving faster, and soon.
Via
The Motley Fool
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
September 16, 2024
There's plenty of upside with this stock, but it might take a while to realize.
Via
The Motley Fool
AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio?
September 08, 2024
The top 10 mid-cap stocks in August: Polestar Automotive, Upstart, Lumen Technologies, GDS Holdings, Tempus AI, Clear Secure, Iovance Biotherapeutics, Evolent Health, Semtech Corp, AST SpaceMobile.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
This Is the Biggest Risk With Iovance Biotherapeutics Stock
September 06, 2024
Investors should brace for dilution.
Via
The Motley Fool
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest
September 03, 2024
Via
Benzinga
Looking Into Iovance Biotherapeutics's Recent Short Interest
August 16, 2024
Via
Benzinga
Iovance Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
August 12, 2024
Via
Benzinga
Iovance Biotherapeutics to Present at Upcoming Conferences
September 03, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
3 Monster Biotech Stocks to Buy Before 2025
September 02, 2024
These companies are nearly in the sweet spot of risk versus reward in biotech.
Via
The Motley Fool
Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?
August 27, 2024
This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace.
Via
The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 16, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
What the Options Market Tells Us About Iovance Biotherapeutics
August 08, 2024
Via
Benzinga
This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock
August 14, 2024
It could demonstrate a few capabilities that no other biotech has as of yet.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
August 12, 2024
Via
Benzinga
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
August 09, 2024
Via
Benzinga
Why Iovance Biotherapeutics Shares Are Soaring Today
August 09, 2024
The biopharma company is proving its recently approved cancer therapy is marketable.
Via
The Motley Fool
Why Is Iovance Bio (IOVA) Stock Up 18% Today?
August 09, 2024
Iovance Biotherapeutics stock is gaining as IOVA investors react to strong Q2 earnings beats and positive guidance for 2024 and 2025.
Via
InvestorPlace
Topics
Earnings
Exposures
Financial
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
August 09, 2024
Iovance Biotherapeutics stock up 23.2% after issuing upbeat guidance for 2024 and 2025, beating Q2 earnings expectations.
Via
Benzinga
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
August 09, 2024
Via
Benzinga
IOVA Stock Earnings: Iovance Biotherapeutics Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
IOVA stock results show that Iovance Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
August 08, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
10 Best Small and Mid-Cap Stocks to Consider Buying in August
August 01, 2024
A shift in market dynamics could favor these 10 growth stocks.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.